BridgeBio · 20 hours ago
Director/Sr. Director, Clinical Pharmacology
Palo Alto - 3160 Porter
Full-time
Hybrid
Lead/Staff, Director/Executive
$215K/yr - $290K/yr
5+ years expBridgeBio is a pioneering biotech company focused on developing life-changing medicines for patients with unmet needs. They are seeking an experienced Director/Sr. Director of Clinical Pharmacology to lead clinical pharmacology strategy and execution for biologics programs, particularly in nonclinical antibody therapeutics.
BiotechnologyHealth CareLife ScienceMedicalPharmaceutical
Responsibilities
Develop and oversee clinical pharmacology strategy for biologics programs across all stages of development
Serve as the CP lead on nonclinical and clinical project teams, providing scientific input on study design, dose selection, PK/PD, and E-R
Lead first-in-human dose selection, PK/PD analyses, including NCA, PopPK/PD, and modeling/simulation
Collaborate with external CRO partners to deliver quantitative support for program decisions
Contribute and author CP content to protocols, SAPs, CSRs, and regulatory submissions (INDs, briefing packages, BLA sections)
Partner cross-functionally (Clinical, Regulatory, Stats, Translational, Nonclinical) to integrate CP into development plans
Establish and maintain CP standards, templates, and oversight of bioanalytical and modeling vendors
Present findings internally and externally with scientific meeting abstracts, posters, and manuscripts
Qualification
Required
PhD, PharmD, or MD in Clinical Pharmacology, PK/PD, Pharmaceutical Sciences, or related field
5–10+ years industry experience (Director) or 10+ years (Sr Director) applying CP in drug development
Direct experience with monoclonal antibodies/biologics, including immunogenicity and TMDD
In depth knowledge in contemporary PK, population PK, QSP modeling concepts, data analysis, and interpretation; demonstrated record in applying these concepts to support pre-clinical and clinical development programs
Proficiency with PK/PD, E-R, and PMx tools (e.g., WinNonlin, NONMEM/Monolix, R)
Strong understanding of bioanalytical guidance and GLP/GxP regulations and regulatory expectations for CP across IND through BLA/MAA
Previous experience working on INDs
Excellent communication, cross-functional collaboration, and leadership capabilities
Vendor management and experience working in fast-paced, matrixed biotech environments
Benefits
401K with 100% employer match on first 3% & 50% on the next 2%
Employee stock purchase program
Pre-tax commuter benefits
Referral program with $2,500 award for hired referrals
Comprehensive health care with 100% premiums covered - no cost to you and dependents
Mental health support via Spring Health (6 therapy sessions & 6 coaching sessions)
Hybrid work model - employees have the autonomy in where and how they do their work
Unlimited flexible paid time off - take the time that you need
Paid parental leave - 4 months for birthing parents & 2 months for non-birthing parents
Flex spending accounts & company-provided group term life & disability
Subsidized lunch via Forkable on days worked from our office
We provide career pathing through regular feedback, continuous education and professional development programs via LinkedIn Learning, LifeLabs, Spring Health & BetterUp Coaching
We celebrate strong performance with financial rewards, peer-to-peer recognition, and growth opportunities
Company
BridgeBio
BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.
201-500 employees
H1B Sponsorship
BridgeBio has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (3)
2024 (5)
2023 (4)
2022 (4)
2021 (1)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$4.9BKey Investors
Blue OwlQatar Investment AuthorityKohlberg Kravis Roberts
2026-01-16Post Ipo Debt· $550M
2025-02-25Post Ipo Debt· $500M
2024-03-04Post Ipo Equity· $250M
Leadership Team
Justin To
CEO, Skeletal Dysplasias (QED Therapeutics)
Neil Kumar
CEO and Founder
Recent News
BioWorld Financial Watch
2026-01-17
Company data provided by crunchbase